Artemether-Lumefantrine Supplier and Exporter to Ghana

Malaria is endemic throughout Ghana and remains one of the leading causes of outpatient attendance and hospital admission, particularly among children under five. Artemisinin-based combination therapies such as Artemether-Lumefantrine are the recommended first-line treatment for uncomplicated malaria in Ghana, procured across the public health system, the private retail market, and donor-supported programmes. Demand for quality-assured ACTs is large and continuous.

Pharmaceutical products imported into Ghana require registration with the Food and Drugs Authority (FDA). We work with Ghanaian importer and distributor partners to register Artemether-Lumefantrine for the Ghanaian market, providing the CTD and ACTD dossiers the FDA requires, with regulatory assistance through the process. If you are an established Ghanaian importer looking to add a WHO-GMP ACT to your portfolio, we would like to hear from you.

We manufacture Artemether-Lumefantrine in 20/120 mg, 40/240 mg, and 80/480 mg strengths, in both standard and dispersible tablets for paediatric dosing, important given the malaria burden among Ghanaian children. Packaging and labelling can be configured to the Ghanaian market.

Once registered, Artemether-Lumefantrine can be supplied for Ghanaian government malaria tenders, donor and NGO health programmes, and private-market distribution, with competitive volume pricing, flexible packaging, and private labelling.

MOQ and pricing depend on strength, formulation, packaging, and volume. We handle export logistics and documentation for shipments to Ghana through the port of Tema. Request a quote with your requirements for exact terms.